News from guardant health A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 19, 2018, 08:00 ET Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients at European Society of Medical Oncology Annual Meeting

New data demonstrating the high sensitivity and specificity of the blood-based Guardant360® and GuardantOMNI™ assays, developed by Guardant Health...


Oct 16, 2018, 08:00 ET Lung Cancer Study Published in JAMA Oncology Shows Guardant360 Outperforms Tissue Biopsy Alone in Identification of Targetable Mutations

A prospective study in patients with advanced non-small cell lung cancer (NSCLC) has demonstrated that the blood based Guardant360® assay, developed...


Sep 05, 2018, 19:22 ET SLLIP Study Meets Primary Endpoint, Finds the Guardant360 Assay Performs Similar to Standard-of-Care Tissue Testing in Advanced NSCLC, Investigators to Report at WCLC

Researchers will present data at the 19th World Conference on Lung Cancer (WCLC) showing the SLLIP trial met its primary endpoint of demonstrating...


Jul 19, 2018, 11:00 ET New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients

Researchers from Samsung Medical Center and Guardant Health, Inc. have demonstrated the feasibility of determining a measure analogous to tumor...


Jul 12, 2018, 14:00 ET Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications

Guardant Health announced that it has appointed Leena Das-Young, Pharm.D. to serve as General Manager of its LUNAR program. As Guardant Health's...


Jul 12, 2018, 13:51 ET Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer

Guardant Health, Inc. announced that Palmetto GBA, a Medicare Administrative Contractor and leader in evaluating molecular diagnostic technology...


May 23, 2018, 11:30 ET Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications

Guardant Health announced it and its partners will present 29 abstracts at the ASCO Annual Meeting advancing the science of liquid biopsy across...


Apr 26, 2018, 01:00 ET Guardant Health Publishes Extensive Validation of Guardant360® Assay Comprising Largest-Published Blood-Tissue Comparison

The largest published comparison of comprehensive liquid biopsy results to tissue genotyping demonstrated high positive predictive value for the...


Apr 13, 2018, 02:23 ET Guardant Health to Present Validation Data for the GuardantOMNI™ assay

Guardant Health announced it will present data at the American Association for Cancer Research annual meeting detailing the analytical validation of...


Mar 12, 2018, 10:00 ET Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of GI Cancer Trial

The Guardant360® assay, the leading comprehensive liquid biopsy, will be used to launch a new arm of a nationwide trial run by SCRUM-Japan GI-SCREEN, ...


Mar 12, 2018, 10:00 ET Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial

The Guardant360® assay, the leading comprehensive liquid biopsy, will be used as the sole liquid biopsy in LC-SCRUM-Japan, a nationwide genomic...


Feb 15, 2018, 12:18 ET The Guardant360® Assay Receives Expedited Access Pathway Designation for Breakthrough Devices from FDA

The Guardant360® assay, the leading comprehensive liquid biopsy, received an Expedited Access Pathway (EAP) designation from the United States Food...


Nov 16, 2017, 12:05 ET Guardant Health Expands Support for the Development of the GuardantOMNI™ Assay Through New Agreement with Bristol-Myers Squibb

Guardant Health has added Bristol-Myers Squibb Company to the group of pharmaceutical companies it is working with to develop the GuardantOMNI assay, ...


Nov 15, 2017, 14:03 ET New Research Reveals Molecular Heterogeneity of Metastatic Gastroesophageal Cancer

Researchers from the University of Chicago, Dana-Farber Cancer Institute (DFCI), and Guardant Health, Inc. published new evidence of the genomic...


Nov 06, 2017, 10:37 ET Guardant Health Database Reveals Potential of Targeted Therapy Combinations to Treat Advanced Lung Cancer

Research led by scientists at UC San Francisco and the Francis Crick Institute in London has used Guardant Health's database of comprehensive liquid...


Oct 02, 2017, 11:00 ET Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from Immunotherapy

Oncologists may get a new tool for identifying which of their cancer patients are most likely to respond to widely prescribed immunotherapies, recent ...


Sep 26, 2017, 09:00 ET Guardant Health Receives Investigational Device Exemption Approval from the FDA to Support Merck KGaA, Darmstadt, Germany Tepotinib Study

Guardant Health announced that it received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to...


Jun 27, 2017, 11:00 ET New Studies Demonstrate the Need for and Utility of Comprehensive Liquid Biopsies

Two recent studies demonstrate the unmet medical need for and the clinical utility of a highly sensitive comprehensive liquid biopsy to help manage...


Jun 22, 2017, 11:00 ET Guardant Health Files Lanham Act Lawsuit Against Foundation Medicine Alleging False Advertising

Guardant Health, the leader in comprehensive liquid biopsies, filed a lawsuit against Foundation Medicine, Inc. (FMI), for false advertising and...


Jun 03, 2017, 08:00 ET Guardant Health announces broad, long-term alliance with Pfizer Oncology supporting multiple clinical programs with the Guardant360 assay

Guardant Health announced a broad, long-term alliance with Pfizer Oncology to support several clinical trial programs. A non-exclusive agreement...


May 24, 2017, 12:00 ET New York State Issues Approval for the Guardant360 Assay

Guardant Health announced that the Guardant360® assay has been approved by New York State's Clinical Laboratory Evaluation Program (CLEP). The...


May 18, 2017, 09:00 ET Guardant Health Announces Draft Medicare Local Coverage Determination for the Guardant360 Assay

Guardant Health® announced that Palmetto GBA, a Medicare Administrative Contractor and leader in evaluating molecular diagnostic technology through...


May 11, 2017, 08:00 ET Guardant Health Partners with SoftBank to Accelerate Efforts in Early Cancer Detection

Guardant Health, the world leader in comprehensive liquid biopsies, announced an ambitious goal to sequence the tumor DNA of more than 1 million...


Jan 31, 2017, 08:12 ET MD Anderson and Guardant Health announce partnership to make comprehensive liquid biopsy part of oncology standard of care

The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive...


Jan 06, 2017, 09:01 ET Guardant Health to create a new 500-plus-gene liquid biopsy panel with several leading pharmaceutical companies to accelerate clinical trials and drug development

Guardant Health today announced that it has entered into separate agreements with AstraZeneca, Merck (known as MSD outside the United States and...